Cargando…

Interleukin-6 as a Potential Therapeutic Target for Pulmonary Arterial Hypertension

Interleukin-6 (IL-6) is a pleiotropic cytokine with a wide range of biologic activities in immune regulation, hematopoiesis, inflammation, and oncogenesis. Recent accumulating evidence indicates a pathologic role for IL-6 in promoting proliferation of both smooth muscle and endothelial cells in the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Furuya, Yoshiaki, Satoh, Toru, Kuwana, Masataka
Formato:	Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2010
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2958514/ https://www.ncbi.nlm.nih.gov/pubmed/20981316 http://dx.doi.org/10.1155/2010/720305

Ejemplares similares

Identification of Novel Therapeutic Targets for Pulmonary Arterial Hypertension
por: Satoh, Kimio, et al.
Publicado: (2018)

Rapid Initiation of Intravenous Epoprostenol Infusion Is the Favored Option in Patients with Advanced Pulmonary Arterial Hypertension
por: Kimura, Mai, et al.
Publicado: (2015)

Arterial Hypertension and Interleukins: Potential Therapeutic Target or Future Diagnostic Marker?
por: Tanase, Daniela Maria, et al.
Publicado: (2019)

Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study
por: Kimura, Mai, et al.
Publicado: (2015)

Improvements in French risk stratification score were correlated with reductions in mean pulmonary artery pressure in pulmonary arterial hypertension: a subanalysis of the Japan Pulmonary Hypertension Registry (JAPHR)
por: Tamura, Yuichi, et al.
Publicado: (2021)

Pulmonary arterial hypertension associated with connective tissue disease: meta-analysis of clinical trials
por: Kuwana, Masataka, et al.
Publicado: (2013)

Human Pentraxin 3 (PTX3) as a Novel Biomarker for the Diagnosis of Pulmonary Arterial Hypertension
por: Tamura, Yuichi, et al.
Publicado: (2012)

Pathological Mechanisms and Potential Therapeutic Targets of Pulmonary Arterial Hypertension: A Review
por: Xiao, Ying, et al.
Publicado: (2020)

Potassium Channels as Therapeutic Targets in Pulmonary Arterial Hypertension
por: Redel-Traub, Gabriel, et al.
Publicado: (2022)

Potential therapeutic targets for hypoxia-induced pulmonary artery hypertension
por: Dong, Li, et al.
Publicado: (2014)

Potential biomarkers and therapeutic targets of idiopathic pulmonary arterial hypertension
por: He, Wenjun, et al.
Publicado: (2022)

Potential of the TRPM7 channel as a novel therapeutic target for pulmonary arterial hypertension
por: Hiraishi, Keizo, et al.
Publicado: (2022)

Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension
por: Toshner, Mark, et al.
Publicado: (2022)

Novel diagnostic and therapeutic approaches to pulmonary hypertension due to the unilateral absence of a pulmonary artery
por: Nagamatsu, Yuki, et al.
Publicado: (2021)

Arterial methemoglobin level predicts therapeutic effectiveness of the PDE5 inhibitors in patients with in idiopathic pulmonary arterial hypertension
por: Tamura, Yuichi, et al.
Publicado: (2011)

New Therapeutic Target for Pulmonary Arterial Hypertension
por: Yoon, Kyung Lim
Publicado: (2018)

Interleukin-6: a new therapeutic target
por: Smolen, Josef S, et al.
Publicado: (2006)

Pulmonary Artery Pressure as a Treatment Target to Improve the Prognosis of Idiopathic Pulmonary Arterial Hypertension　― Insight From a Cohort From Two Japanese Pulmonary Hypertension Centers ―
por: Ishiguro, Midori, et al.
Publicado: (2020)

Apelin-APJ Signaling: a Potential Therapeutic Target for Pulmonary Arterial Hypertension
por: Kim, Jongmin
Publicado: (2014)

BMP type II receptor as a therapeutic target in pulmonary arterial hypertension
por: Orriols, Mar, et al.
Publicado: (2017)

Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agent
por: Casserly, Brian, et al.
Publicado: (2009)

The Potential Application and Promising Role of Targeted Therapy in Pulmonary Arterial Hypertension
por: Hsieh, Meng-Chien Willie, et al.
Publicado: (2022)

Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor
por: Dayer, Jean-Michel, et al.
Publicado: (2010)

Epigenetic Mechanisms as Emerging Therapeutic Targets and Microfluidic Chips Application in Pulmonary Arterial Hypertension
por: Ho, Linh, et al.
Publicado: (2022)

Prostaglandin and prostaglandin receptors: present and future promising therapeutic targets for pulmonary arterial hypertension
por: Zeng, Cheng, et al.
Publicado: (2023)

Efficacy, safety, and pharmacokinetics of inhaled treprostinil in Japanese patients with pulmonary arterial hypertension
por: Kuwana, Masataka, et al.
Publicado: (2023)

Circulating Interleukin-7 in Human Pulmonary Arterial Hypertension
por: Diekmann, Franziska, et al.
Publicado: (2021)

Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension
por: Di Benedetto, Paola, et al.
Publicado: (2020)

Interleukin-22: a potential therapeutic target in atherosclerosis
por: Luo, Jin-Wen, et al.
Publicado: (2021)

Interleukin-6: a new therapeutic target in systemic sclerosis?
por: O'Reilly, Steven, et al.
Publicado: (2013)

Therapeutic Evaluation of Antibody-Based Targeted Delivery of Interleukin 9 in Experimental Pulmonary Hypertension
por: Gouyou, Baptiste, et al.
Publicado: (2021)

Interleukin-6 and pulmonary hypertension: from physiopathology to therapy
por: Xu, Wei-Jie, et al.
Publicado: (2023)

Neprilysin: A Potential Therapeutic Target of Arterial Hypertension?
por: Salazar, Juan, et al.
Publicado: (2020)

Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis
por: Kuwana, Masataka, et al.
Publicado: (2020)

Piezo1 in vascular remodeling of atherosclerosis and pulmonary arterial hypertension: A potential therapeutic target
por: Xu, Han, et al.
Publicado: (2022)

Cannabinoids in arterial, pulmonary and portal hypertension – mechanisms of action and potential therapeutic significance
por: Malinowska, Barbara, et al.
Publicado: (2018)

Epigenetic modulation as a therapeutic approach for pulmonary arterial hypertension
por: Kim, Jun-Dae, et al.
Publicado: (2015)

A review of therapeutic agents for the management of pulmonary arterial hypertension
por: Hahn, Stella S, et al.
Publicado: (2016)

Transcription factors and potential therapeutic targets for pulmonary hypertension
por: Yang, Liu, et al.
Publicado: (2023)

Therapeutic implications of microRNAs in pulmonary arterial hypertension
por: Lee, Aram, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_qifmui770n2jj5onk14ipggais